VERAXA Biotech (NASDAQ: VRXA) announced on July 27, 2026, that its bispecific antibody-drug conjugate (bsADC) program, VXA-222, has reached a key technical milestone under its collaboration with OmniAb. The company stated that OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach, intended to improve precision in treating solid tumors.
Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products.
This advancement is significant for the biopharmaceutical industry as bispecific ADCs represent a next-generation therapeutic modality. By targeting two antigens simultaneously, VXA-222 could potentially reduce off-target effects and improve efficacy in solid tumors, which are notoriously difficult to treat. For business leaders, the progress underscores the value of strategic partnerships in accelerating drug development and the potential for innovative ADC platforms to address unmet medical needs.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company leverages a suite of transformative technologies and quality-by-design principles to advance its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
For investors, the milestone could signal reduced risk and increased confidence in VERAXA's pipeline. The collaboration with OmniAb allows VERAXA to access advanced antibody discovery tools without bearing the full upfront cost, potentially improving capital efficiency. However, as with all early-stage programs, VXA-222 faces risks related to clinical development, regulatory approval, and commercialization.
Forward-looking statements in the announcement highlight risks and uncertainties, including those detailed in the company's SEC filings. The full press release is available at https://ibn.fm/qMRuJ. For more information on VERAXA and its latest news, visit the company’s newsroom at https://ibn.fm/VRXA.
